Oxford Drug Design

Oxford Drug Design is an innovative biotechnology startup that has its roots as a spinout from Oxford University. The company is focused on oncology and has developed pioneering computational methods to support its drug discovery efforts. With a strong emphasis on designing novel therapeutics with differentiated modes of action against cancer and other challenging diseases, the company aims to achieve superior patient outcomes. One of the key strengths of Oxford Drug Design lies in its unique integration of dual core competences in aminoacyl-tRNA synthetase enzymes and advanced AI/ML methods. This distinctive approach has enabled the company to rapidly expand its pipeline with a specific focus on oncology. The company has managed to validate its drug discovery platform by swiftly discovering novel therapeutic candidates with highly innovative chemical scaffolds and modes of action. Founded in 2001 and headquartered in the United Kingdom, Oxford Drug Design recently secured a significant investment of £2.20M through a Convertible Note investment on 19th May 2022. The investors involved in this latest funding round include Angel CoFund, R42, o2h Ventures, and Meltwind Advisory. This injection of capital is expected to further propel the company's efforts in developing groundbreaking therapeutics in the field of oncology. Follow Oxford Drug Design on Twitter @OxDrugDes for the latest updates on their innovative drug discovery journey.